Quidelortho Corp Stock Fair Value Calculator – QUIDELORTHO CORP Reports Second Quarter Earnings Results for FY2023

August 23, 2023

🌥️Earnings Overview

QUIDELORTHO CORP ($NASDAQ:QDEL) reported on June 30 2023 its earnings results for the second quarter of FY2023. Revenue was recorded at USD 665.1 million, an 8.4% increase from the same quarter of the prior year, while net income was recorded at USD -53.2 million compared to 19.3 million in the same quarter of the past year.

Market Price

After the release of the reports, their stock opened at $82.9 and closed at $82.3, which was a decrease of 2.0% from the previous closing price of 83.9. This marked the first time in three quarters that the stock price had decreased. Analysts were quick to point out that despite the downturn, QUIDELORTHO CORP’s overall performance was still promising. QUIDELORTHO CORP attributes much of their success to their strong commitment to innovation and customer service. They have invested heavily in research and development to develop new products and services as well as improving existing offerings.

Additionally, they have placed a focus on providing the best customer experience possible and it has paid off as customer satisfaction ratings have been high. Investors should look to the future with optimism as the company is well-positioned to capitalize on any opportunities that arise. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Quidelortho Corp. More…

    Total Revenues Net Income Net Margin
    3.16k 45.1 3.4%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Quidelortho Corp. More…

    Operations Investing Financing
    318 -200.3 -317
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Quidelortho Corp. More…

    Total Assets Total Liabilities Book Value Per Share
    8.55k 3.55k 74.89
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Quidelortho Corp are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    69.0% 17.1% 7.0%
    FCF Margin ROE ROA
    3.4% 2.7% 1.6%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Quidelortho Corp Stock Fair Value Calculator

    At GoodWhale, we have performed an analysis of QUIDELORTHO CORP‘s wellbeing and have calculated the intrinsic value of its share to be around $131.5. This value was calculated using our proprietary Valuation Line, which is a comprehensive framework for understanding a company’s worth. Notably, the intrinsic value of QUIDELORTHO CORP is significantly higher than what the stock is currently traded at ($82.3). This means that the stock is currently undervalued by 37.4%. Since the stock is trading at a discount, this presents an interesting opportunity for investors looking to get into the company. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    Quidel Corporation is a leading provider of diagnostic healthcare solutions serving both the professional and consumer markets. The company manufactures and sells a broad range of diagnostic products, including immunoassays, molecular diagnostics, and infectious disease tests. Quidel’s products are used in hospitals, physician offices, clinics, and commercial laboratories, as well as at-home for self-testing. Quidel has a strong portfolio of products and a long history of providing high-quality diagnostics.

    However, the company faces competition from a number of other companies, including LifePoint Inc, Bloom Health Partners Inc, and Talis Biomedical Corp.

    – LifePoint Inc ($OTCPK:LFPI)

    LifePoint Inc is a company that provides healthcare services. It has a market cap of 10.21k as of 2022 and a Return on Equity of 8.83%. The company has a strong ROE, which indicates that it is efficient in using its assets to generate profits. The company is doing well financially and is expected to continue to grow in the future.

    – Bloom Health Partners Inc ($OTCPK:BLMHF)

    The company’s market cap is 2.86M as of 2022. The company’s ROE is 26.8%. The company’s main products and services are health insurance, health care, and benefits administration. Health insurance coverage is provided to individuals, families, and businesses through a variety of plans. Health care services are delivered through a network of providers. Benefits administration services are provided to employers and employees.

    – Talis Biomedical Corp ($NASDAQ:TLIS)

    Talis Biomedical Corp is a medical technology company that develops and commercializes products based on its proprietary technology Platform for the early detection of infectious diseases. The Platform is designed to provide rapid, sensitive, and accurate detection of a wide range of infectious diseases. Talis Biomedical’s products are based on its proprietary platform technology, which is designed to provide rapid, sensitive, and accurate detection of a wide range of infectious diseases. Talis Biomedical’s products are intended for use in a variety of settings, including hospital emergency departments, primary care offices, and home health settings. Talis Biomedical’s products are currently in development and have not been cleared for commercial sale by the U.S. Food and Drug Administration.


    QUIDELORTHO CORP reported its earnings results for the second quarter of FY2023, with total revenue increasing 8.4% year-over-year to USD 665.1 million. However, net income decreased significantly, from 19.3 million in the same quarter of the prior year to -53.2 million, resulting in a large net loss. Investors should carefully examine the underlying factors causing this large discrepancy between revenue and income, and consider whether this may be a meaningful indicator for the company’s future performance.

    Recent Posts

    Leave a Comment